What Hovione does

Hovione is a family-owned integrated Contract Development and Manufacturing Organization (CDMO) founded in 1959 in Lisbon and headquartered in Loures, Portugal. The company provides end-to-end pharmaceutical services spanning drug substance development, particle engineering (spray drying, jet milling, hot melt extrusion), drug product manufacturing including continuous tableting, and proprietary inhalation and nasal drug delivery devices. Its technology stack includes the ASD-HIPROS intelligent screening platform, the Dispersome solubility enhancement technology, HPAPI containment down to OEL 0.03 µg/m³, and a portfolio of patented dry powder inhalers (Sunriser, TwinCaps, Large Dose, PowdAir, Papillon) developed with partners H&T Presspart and IDC. Hovione also supplies off-patent API products and licenses device and formulation technologies.

Hovione serves 19 of the world's top 20 pharmaceutical companies through a B2B enterprise sales model based on long-term development and supply agreements, with revenue generated from CDMO service fees, manufacturing supply, and technology/device licensing. It operates manufacturing and R&D sites in Portugal (Loures, Seixal, Lisbon), the United States (East Windsor, New Jersey), Ireland (Cork), and Macau, supported by regional sales and customer support offices in Switzerland, Japan, China (Shanghai, Beijing), Hong Kong, and India. The company employs approximately 2,500-2,600 people including more than 300 scientists and reports that its products reach roughly 80 million patients annually, participating in up to 10% of FDA-approved new medicines.

The business model combines fee-for-service CDMO contracts, commercial supply agreements, device licensing royalties, and licensing of specialty formulation technology. Customer segments are horizontal: large pharmaceutical companies (primary), biotechnology companies (early-phase), and generic pharmaceutical companies (off-patent APIs). The company's positioning emphasizes solubility and bioavailability challenges for BCS Class 2/4 molecules, with proprietary capabilities in spray-dried amorphous solid dispersions, continuous manufacturing, and pulmonary/nasal delivery, backed by a multi-decade regulatory track record including a recent 'zero observation' FDA inspection.

Name

Hovione

Legal name

Hovione FarmaCiencia S.A.

Website

https://hovione.com

Company type

Private

Founded year

1959

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Hovione is a family-owned, integrated pharmaceutical CDMO founded in 1959 in Portugal, providing drug substance development, particle engineering (spray drying), and drug product manufacturing, including proprietary inhalation and nasal devices, to 19 of the world's top 20 pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Contract pharmaceutical manufacturing
• Drug substance development
• Particle engineering services
• Spray drying CDMO
• Inhalation drug delivery

Headquarters

HQ city

Loures

HQ country

Portugal

HQ region

Europe

Offices13 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Full-service CDMO providing drug substance manufacturing, particle engineering, and drug product manufacturing services to pharmaceutical customers. Revenue generated through development fees, manufacturing fees, and long-term supply agreements.
2. Off-patent API Products: Niche generic API products portfolio including corticosteroids. Manufactured and supplied to pharmaceutical customers.
3. Device Licensing and Supply: Proprietary inhaler devices (Sunriser, TwinCaps, Papillon, PowdAir, Large Dose DPI) available for licensing and supply to pharmaceutical partners.
4. Technology Licensing: Dispersome technology available for licensing on exclusive basis within product scope with possible life cycle extension beyond 2040.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Hovione is an integrated pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services from drug substance development (API synthesis, HPAPI handling) through particle engineering (spray drying, jet milling, hot melt extrusion) to drug product manufacturing (continuous tableting, inhalation and nasal devices, sterile fill-finish). The company also offers proprietary inhaler devices (Sunriser, TwinCaps, Papillon, PowdAir, Large Dose) and the Dispersome solubility-enhancement technology for licensing, and supplies a niche portfolio of off-patent APIs including corticosteroids.

Product overview

Hovione is a specialist integrated Contract Development and Manufacturing Organization (CDMO) offering end-to-end pharmaceutical services from drug substance development through drug product manufacturing. The core portfolio centers on particle engineering technologies including spray drying, jet milling, hot melt extrusion, and continuous tableting, complemented by a comprehensive range of inhalation and nasal drug delivery devices (Sunriser® DPI, TwinCaps® DPI, Large Dose DPI, PowdAir® DPI, Papillon DPI) developed in partnership with H&T Presspart and IDC. Specialty offerings include the Dispersome® solubility enhancement technology with ASD-HIPROS intelligent screening platform, highly potent API (HPAPI) handling, and continuous flow manufacturing. The company operates global manufacturing sites in Portugal, Ireland, Macau, and New Jersey, and serves 19 of the world's top 20 pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

• Sunriser DPI: High-performance capsule-based dry powder inhaler capable of delivering up to 50mg per dose with >50% lung delivery performance.
• TwinCaps DPI
• Dispersome
• ASD-HIPROS
• HPAPI

Products and services

• Contract Manufacturing Services (Integrated CDMO) End-to-end pharmaceutical CDMO services from drug substance development (API synthesis, HPAPI, continuous flow) through particle engineering (spray drying, jet milling, hot melt extrusion) to drug product manufacturing (continuous tableting, inhalation and nasal drug product, sterile fill-finish), sold to pharmaceutical customers.
• Off-patent API Products Portfolio of off-patent active pharmaceutical ingredients, notably corticosteroids, manufactured and supplied to pharmaceutical customers, with API portfolio, exclusive partnerships, and high value applications.
• Sunriser DPI Patented high-performance capsule-based dry powder inhaler capable of delivering up to 50 mg per dose with >50% lung delivery performance, for both carrier-based and spray-dried engineered formulations, available for licensing and supply to pharmaceutical partners.
• TwinCaps DPI World's largest selling disposable dry powder inhaler, market approved and used to deliver Daiichi-Sankyo's Inavir for influenza treatment in Japan; delivers up to 2x30 mg, available for licensing and supply.
• Large Dose DPI (TwinMax / 8Shot) Disposable DPI platform for high-dose drug delivery with dose configurations of 2x50 mg (TwinMax) and 8x30 mg (8Shot), available for licensing and supply.
• PowdAir DPI Easy-to-use, multi-use capsule DPI with automatic capsule opening for asthma, COPD, and CF applications, available for off-the-shelf supply to pharmaceutical partners.
• Papillon DPI Ultra-affordable, multi-use blister DPI supporting single or two separate blisters for single or combination therapies, available for licensing and supply.
• Dispersome Solubility Enhancement Technology Proprietary solubility enhancement technology using a naturally occurring excipient (Beta-Lactoglobulin) to develop amorphous solid dispersions with high drug loading (>50% w/w) and high bioavailability, available for licensing on an exclusive basis within product scope.
• HPAPI (Highly Potent API) Manufacturing Services Specialized contract manufacturing services for highly potent active pharmaceutical ingredients with OEL <10 µg/m³, including drug substance and particle engineering with special containment, offered to pharmaceutical customers.
• Intranasal Drug Delivery Platform End-to-end intranasal drug delivery platform spanning API synthesis, advanced formulation and particle engineering, filling, and device technologies, featuring a single-use nasal dry powder device with patented mechanism for targeted nasal deposition and potential nose-to-brain delivery.

Quantifiable outcome

• Products reach approximately 80 million patients annually
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Seven partnerships are on record, tiered core and supporting.

• Industrial Design Consultancy Ltd (IDC)coreTechnology or Integration · 1 May 2026Strategic collaboration to develop intranasal drug delivery platform. The lead single-use nasal dry powder device is now available for commercial partnerships. Platform integrates nasal particle engineering, formulation manufacturing, filling, and device technologies. Companies are also developing a multi-dose variant. The collaboration is backed by an intellectual property portfolio and initial patent grants.
• ExtremoChem LdacoreOthers · 16 November 2023Hovione acquired ExtremoChem Lda, a startup specializing in synthetic sugars for biopharmaceutical stabilization. Proprietary sugars improve stability, viscosity reduction, and delivery of proteins and biopharmaceuticals. This expands Hovione's technology platform in pharmaceutical development and manufacturing.
• H&T PresspartcoreStrategic or Co-development Partner · 1 May 2023Partnership for advanced dry powder inhaler technology development. The Sunriser DPI was developed through this partnership. Sunriser features unique capsule movement enabling best-in-class delivery efficiency for both carrier-based and spray-dried engineered formulations.
• GEAcoreTechnology or IntegrationStrategic collaboration on continuous tableting technology. Partnership includes ConsiGma CDC Flex next-generation continuous tableting machine designed for easier use, more compact footprint, and accelerated development. Companies co-host webinars and educational content on continuous manufacturing.
• Zerion PharmacoreStrategic or Co-development PartnerPartnership to advance Dispersome technology for bioavailability enhancement of small-molecule drugs. Supported by Hovione's ASD-HIPROS intelligent screening platform to speed amorphous solid dispersion formulation development. Dispersome enables high drug loading above 50% w/w with possible life cycle extension beyond 2040.
• Dragonfly TechnologiessupportingTechnology or IntegrationPartnership for micellar chemistry enabling sustainable chemistry in water. Applied to various reactions including amide bond formation, SNAr, Suzuki couplings, nitro reductions, and Buchwald-Hartwig amination.
• MicroinnovasupportingTechnology or IntegrationPartnership for flow chemistry enabling greener, leaner chemical processes. Supports sustainable chemistry initiatives.

Scale indicators10 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Cambrex: Cambrex is a small-molecule-focused CDMO with strengths in API development and manufacturing plus finished dosage forms; acquired by Permira in 2019. Comparable to Hovione's drug substance / drug product focus and small-molecule specialization.
• Lonza: Lonza is the world's largest integrated CDMO, offering both drug substance (small and large molecule APIs) and drug product services to global pharmaceutical customers. Most directly comparable to Hovione in scope (API + drug product), end-market (large pharma), and integrated CDMO model, though Lonza is materially larger and biologics-weighted.
• Catalent: Catalent is a major CDMO with strong inhalation drug delivery (including spray drying) and softgel/oral dose capabilities serving large pharma. Comparable to Hovione on the inhalation/particle engineering axis and B2B pharma CDMO model; acquired by Novo Holdings in late 2024.
• Recipharm: Recipharm is a European integrated CDMO offering drug substance and drug product services (including inhalation and sterile fill-finish) to pharma customers; acquired by EQT in 2022. Comparable to Hovione as a European-headquartered integrated CDMO with similar customer profile.
• Aenova Group: Aenova is a European-headquartered CDMO offering solid dosage forms, APIs, and softgel capsules to pharma customers. Comparable to Hovione in integrated European CDMO model serving large pharmaceutical companies.
• Siegfried Holding: Siegfried is a Swiss integrated CDMO offering API and drug product services, including continuous manufacturing, with a comparable European footprint and similar customer base of global pharma companies. Comparable to Hovione in integrated small-molecule CDMO services and customer profile.
• Alcami Corporation: Alcami is a US-headquartered CDMO offering drug substance (API), drug product, and analytical services to pharmaceutical companies. Comparable to Hovione on the integrated CDMO model and pharma customer base, with similar scale.

Emerging players

• H&T Presspart: H&T Presspart is a drug delivery device manufacturer focused on inhalation (DPIs, metered-dose inhalers) and partner in Hovione's Sunriser DPI development. Comparable as an inhalation device specialist in Hovione's ecosystem; partial overlap on the device side rather than full-service CDMO.

Broad incumbents

• Evonik Health Care: Evonik operates a Health Care business line covering API manufacturing (including HPAPIs) and CDMO services. Hovione's CEO Jean-Luc Herbeaux was previously at Evonik; comparable in API and HPAPI CDMO capability, though Evonik is far broader as a specialty chemicals conglomerate.
• Patheon (Thermo Fisher Scientific): Patheon, now part of Thermo Fisher's pharma services segment, is a global CDMO offering API and drug product services across a broader portfolio including clinical research. Comparable as a large incumbent CDMO serving top-20 pharma, but with a much wider service portfolio than Hovione's specialist integrated offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/HovioneGroup
• YouTubeyoutube.com/c/HovioneGroup
• Facebookfacebook.com/hovione.en
• LinkedInlinkedin.com/company/hovione
• Instagraminstagram.com/hovionegroup

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hovione